Comparative Pharmacology
Head-to-head clinical analysis: ESIDRIX versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESIDRIX versus METAHYDRIN.
ESIDRIX vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis and decreased extracellular volume.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
25-50 mg orally once daily; may increase to 100 mg once daily or 50 mg twice daily for resistant edema.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 10-15 hours (mean 12 hours); clinical context: half-life prolonged in renal impairment, requiring dose adjustment.
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Renal: approximately 70% excreted unchanged in urine; biliary/fecal: less than 10%.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic